We demonstrate that after 3 yr of prostate-specific-antigen (PSA) testing, we detect more serious prostate cancers in men with BRCA2 mutations than those without these mutations. We recommend that male BRCA2 carriers are offered systematic PSA screening.
We surveyed physicians globally about their experience in treating patients with advanced prostate cancer and genetic testing. Physicians reported that half of patients are recommended…
Optimal follow-up for testicular cancer is not well defined. We prospectively analysed the clinical impact of different imaging modalities for detection of relapse in the…
This special issue aims to explore how urology will continue to adapt to meet the needs of a changing population. John Lacy, MD University of…
We show that longer exposure to 177Lu-PSMA-617 treatment for up to six cycles was not associated with greater toxicity risk. Safety analyses support a favourable…
The COVID-19 has been a great challenge for healthcare providers all over the world which overwhelmed patients and healthcare providers by postponing …
Venous thromboembolism (VTE) is associated with various long-term complications. We aimed to investigate the association of clinical characteristics at VTE diagnosis with functional limitations three…
We show that longer exposure to 177Lu-PSMA-617 treatment for up to six cycles was not associated with greater toxicity risk. Safety analyses support a favourable…
Bladder neck contractures (BNCs) are a well-documented, but acceptably uncommon late adverse outcome of surgical treatment for benign prostatic hyperp…
The ability of health care professionals to communicate with patients compassionately and effectively is crucial for shared decision-making, but littl…
Read the latest articles of Data in Brief at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature
